Role of Mef2D in inflammation
Role of Mef2D in inflammation
批准号:
MR/L008785/1
负责人:
Simon Arthur
金额:
$43.89万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2014
资助国家:
英国
项目状态:
已结题
起止时间:
2014 至 --
中文摘要
免疫系统是必不可少的,以防止感染和调解组织修复。尽管免疫系统有这些重要的功能,但如果没有得到正确的调节,就会产生有害的影响。感染后,免疫系统中的细胞检测到病原体,然后引发炎症反应。这一过程导致更多免疫细胞的招募和激活,目的是杀死病原体。一旦病原体被清除,免疫系统就会失效,这一过程被称为分解。虽然炎症是应对感染的必要过程,但这一过程的副作用是对身体健康细胞的不必要的附带损害。为了尽量减少这种影响,炎症是一个严格控制的过程,并受到一系列正反馈和负反馈机制的影响,以防止不受控制的炎症,并在病原体被杀死后促进其解决。免疫细胞在炎症期间的协调是通过产生一系列促炎性和抗炎性细胞因子来实现的,这些细胞因子是控制免疫细胞功能的小蛋白质。由于它们在调节免疫系统中的重要性,这些细胞因子的产生受到严格的调节,这种调节的失败会导致严重的后果。例如,在感染期间未能限制炎症可能导致促炎细胞因子的不受控制的产生,即使感染得到控制也会持续存在。这些“细胞因子风暴”可导致感染性休克,非常难以治疗,仍然导致高死亡率。不能促进炎症的消退或免疫耐受的破坏导致慢性炎症,这是一系列疾病的病理基础,包括自身免疫性疾病、糖尿病和心血管疾病。因此,调节细胞因子的产生或功能以使免疫系统失活的药物具有治疗一系列疾病的潜力。了解细胞内调节细胞因子产生的机制及其对免疫系统的影响是选择可用于药物开发的靶点的重要第一步。我们感兴趣的是如何控制抗炎细胞因子IL-10的产生。IL-10是限制炎症和促进炎症消退的关键细胞因子。研究发现,由于对肠道菌群的免疫反应失调,使IL-10基因失活或阻断IL-10功能的突变会导致小鼠和人类发生结肠炎。此外,IL-10功能的丧失已被证明在大范围的免疫模型中使小鼠对病理敏感。在我们之前的工作中,我们研究了IL-10基因的转录是如何被调节的,并开始揭示控制其表达的细胞内途径。最近,我们发现巨噬细胞是先天免疫中的一种重要细胞类型,IL-10的产生被Mef2D抑制,Mef2D是一种以前未被证实在巨噬细胞功能中起作用的蛋白质。Mef2D是一种可以与DNA结合并调节特定基因转录的转录因子,在IL-10基因中存在Mef2D的潜在位点。在我们的工作中,我们将确定Mef2D调节巨噬细胞中IL-10的分子机制以及控制Mef2D功能的信号通路。我们还将确定Mef2D是否在免疫系统中产生IL-10的其他细胞类型中发挥类似的作用。最后,我们将确定体内阻断Mef2D功能对IL-10依赖性免疫疾病模型的影响。总之,这些实验将有助于描绘一条控制IL-10产生的新途径。反过来,这将提出新的方法,IL-10的产生可以被设计用于限制炎症的药物靶向。
英文摘要
The immune system is essential in order to protect from infection and to mediate tissue repair. Despite these important functions the immune system, when not correctly regulated, can have harmful effects. Following infection, pathogens are detected by cells in the immune system, which then trigger an inflammatory reaction. This process results in the recruitment and activation of further immune cells and is designed to kill the pathogen. Once the pathogen is cleared then the immune system is deactivated, a process referred to as resolution. While inflammation is a necessary process to deal with infection, a side effect of this process is unwanted collateral damage to healthy cells in the body. To minimize this effect, inflammation is a tightly controlled process and subject to a range of both positive and negative feedback mechanisms to both prevent uncontrolled inflammation and promote its resolution once pathogens are killed. Co-ordination of immune cells during inflammation is achieved via the production of a range of pro- and anti-inflammatory cytokines, small proteins that control the function of immune cells. Due to their importance in regulating the immune system, the production of these cytokines is tightly regulated and failure of this regulation has serious consequences. For example, failure to limit inflammation during infection can lead to a uncontrolled production of pro-inflammatory cytokines that persists even if the infection is controlled. These 'cytokine storms' can lead to septic shock and are very difficult to treat and still result in a high rate of mortality. An inability to promote the resolution of inflammation or a breakdown in immune tolerance results in chronic inflammation, a condition that underlies pathology in a range of diseases including autoimmune conditions, diabetes and cardiovascular disease.Drugs that modulate the production or function of cytokines to inactivate the immune system therefore have potential for the treatment of a range of conditions. Understanding the intracellular mechanisms that regulate cytokine production and how this impacts on the immune system is an important first step in selecting targets that can be used for drug development. We are interested in how the production of an anti-inflammatory cytokine, IL-10, is controlled. IL-10 is a key cytokine in limiting inflammation and promoting resolution. This is illustrated by the finding that mutations that either inactivate the IL-10 gene or block IL-10 function result in the development of colitis in both mice and humans due to a deregulated immune response to the gut flora. In addition loss of IL-10 function has been shown to sensitize mice to pathology in a large range on immune models. In our previous work, we have looked at how transcription of the IL-10 gene is regulated and started to unravel the intracellular pathways that control its expression. Recently we have found that in macrophages, an important cell type in innate immunity, IL-10 production is inhibited by Mef2D, a protein that was not previously established to play a role in macrophage function. Mef2D is a transcription factor that can bind to DNA and regulate the transcription of specific genes and a potential site for Mef2D exists in the IL-10 gene. In the proposed work, we will determine the molecular mechanism by which Mef2D regulates IL-10 in macrophages and the signaling pathways that control Mef2D function. We will also determine if Mef2D plays a similar role in other cell types in the immune system that produce IL-10. Finally we will determine what the effect blocking Mef2D function in vivo has on IL-10 dependent models of immune disease. Together these experiments will help delineate a new pathway that controls the production of IL-10. This in turn will suggest novel ways in which IL-10 production could be targeted by drugs designed to limit inflammation.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1038/srep17316
发表时间:
2015-11-27
期刊:
Scientific reports
影响因子:
4.6
作者:
[Lang E, Bissinger R, Fajol A, Salker MS, Singh Y, Zelenak C, Ghashghaeinia M, Gu S, Jilani K, Lupescu A, Reyskens KM, Ackermann TF, Föller M, Schleicher E, Sheffield WP, Arthur JS, Lang F, Qadri SM]
通讯作者:
Qadri SM
DOI:
10.1074/jbc.m117.805424
发表时间:
2018-02-16
期刊:
The Journal of biological chemistry
影响因子:
--
作者:
[Sutavani RV, Phair IR, Barker R, McFarlane A, Shpiro N, Lang S, Woodland A, Arthur JSC]
通讯作者:
Arthur JSC
DOI:
10.3389/fimmu.2015.00607
发表时间:
2015
期刊:
Frontiers in immunology
影响因子:
7.3
作者:
[McGuire VA, Arthur JS]
通讯作者:
Arthur JS
DOI:
10.1177/2472555217717473
发表时间:
2017-12
期刊:
SLAS discovery : advancing life sciences R & D
影响因子:
--
作者:
[Heap RE, Hope AG, Pearson LA, Reyskens KMSE, McElroy SP, Hastie CJ, Porter DW, Arthur JSC, Gray DW, Trost M]
通讯作者:
Trost M
DOI:
10.1038/srep31159
发表时间:
2016-08-08
期刊:
Scientific reports
影响因子:
4.6
作者:
[McGuire VA, Ruiz-Zorrilla Diez T, Emmerich CH, Strickson S, Ritorto MS, Sutavani RV, Weiβ A, Houslay KF, Knebel A, Meakin PJ, Phair IR, Ashford ML, Trost M, Arthur JS]
通讯作者:
Arthur JS
Development of novel JAK3 inhibitors for the treatment of autoimmunity.
-
批准号:MR/M025233/1
-
项目类别:Research Grant
-
资助金额:$52.69万
-
财政年份:2016
-
负责人:Simon Arthur
-
依托单位:
Understanding the molecular pathways that underlie dectin-1 mediated cytokine responses
-
批准号:MR/L000849/1
-
项目类别:Research Grant
-
资助金额:$54.63万
-
财政年份:2014
-
负责人:Simon Arthur
-
依托单位:
国内基金
海外基金
登录
查看更多内容
成肌样肿瘤周细胞通过p300乙酰化修饰MEF2D介导肺癌免疫抑制型围血管生态位形成的机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:15.0万元
-
批准年份:2024
-
负责人:白雪
-
依托单位:
2 型糖尿病血管钙化新机制 :巨噬细胞外泌体Mef2d 抑制
ArsR 活化肠道脆弱拟杆菌
-
批准号:2024JJ6407
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:陈聪
-
依托单位:
MEF2D上调NET-DNA新型感受器ITGB4促进肝癌肝内转移的机制研究
-
批准号:82373024
-
项目类别:面上项目
-
资助金额:49万元
-
批准年份:2023
-
负责人:向俊宇
-
依托单位:
高糖诱导MEF2D选择性剪切促进巨噬细胞M1极化介导2型糖尿病血管慢性炎症的机制研究
-
批准号:2023JJ60052
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:谢海涛
-
依托单位:
高危MEF2D融合基因在急性B淋巴细胞白血病中的靶向治疗研究
-
批准号:82300167
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:张铭
-
依托单位:
转录因子MEF2D激活TASP1促进结肠癌细胞干性和增殖的分子机制研究
-
批准号:--
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2022
-
负责人:陈燕燕
-
依托单位:
MEF2D 信号通路调控铁死亡介导卵巢癌铂耐药机制研究
-
批准号:2022JJ30868
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2022
-
负责人:张永晶
-
依托单位:
响应ECM-FAK信号的泛素化分子开关决定MEF2D蛋白稳定性进而促进肝癌转移的机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:李先锋
-
依托单位:
基于MEF2D的SUMO/去SUMO化修饰调节探讨SENP3促进病理性心肌肥大的作用及机制研究
-
批准号:82104163
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:李景艳
-
依托单位:
糖尿病血管炎症新机制:高糖环境巨噬细胞miR-32 靶向MEF2D 进而抑制自噬诱导M1 极化
-
批准号:2021JJ70113
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:陈聪
-
依托单位: